PlainRecalls
FDA Drug Moderate Class II Terminated

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Reported: May 18, 2022 Initiated: May 2, 2022 #D-0855-2022

Product Description

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Reason for Recall

Defective container: loose crimp defect, potential loss of container integrity.

Details

Recalling Firm
Amgen, Inc.
Units Affected
15,823
Distribution
Nationwide in the USA, Egypt and Lithuania.
Location
Thousand Oaks, CA

Frequently Asked Questions

What product was recalled?
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01. Recalled by Amgen, Inc.. Units affected: 15,823.
Why was this product recalled?
Defective container: loose crimp defect, potential loss of container integrity.
Which agency issued this recall?
This recall was issued by the FDA Drug on May 18, 2022. Severity: Moderate. Recall number: D-0855-2022.